Literature DB >> 29404083

Updates in Chronic Obstructive Pulmonary Disease for the Year 2014.

Sibel Atış Naycı1, Lütfi Çöplü2, Alev Gürgün3, Nurdan Köktürk4, Mehmet Polatlı5, Elif Şen6, Sema Umut7, Esra Uzaslan8, Nurhayat Yıldırım7, Peter J Barnes9.   

Abstract

Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality in the world. Research conducted over the past decade has contributed much to our current knowledge of the pathogenesis and treatment of COPD. Additionally, an evolving literature has recently accumulated information about the management of COPD and also about exacerbations. This article reviews a concise summary on the updates in COPD including 1) new pathogenic mechanisms and therapeutic targets, 2) management of patients in Group B, C and D according to GOLD 2014 report; 3) prevention and management of exacerbation; 4) monitoring of natural history; and 5) essential but usually forgotten parts of the management.

Entities:  

Keywords:  COPD; disease management; exacerbation; natural history

Year:  2015        PMID: 29404083      PMCID: PMC5783065          DOI: 10.5152/ttd.2015.4555

Source DB:  PubMed          Journal:  Turk Thorac J        ISSN: 2148-7197


  70 in total

1.  Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study.

Authors:  J Garcia-Aymerich; P Lange; M Benet; P Schnohr; J M Antó
Journal:  Thorax       Date:  2006-05-31       Impact factor: 9.139

Review 2.  Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis.

Authors:  J Wang; B Nie; W Xiong; Y Xu
Journal:  J Clin Pharm Ther       Date:  2011-07-11       Impact factor: 2.512

Review 3.  Defective phagocytosis in airways disease.

Authors:  Louise E Donnelly; Peter J Barnes
Journal:  Chest       Date:  2012-04       Impact factor: 9.410

4.  Measuring and quantifying acute exacerbations of COPD: pitfalls and practicalities.

Authors:  Shawn D Aaron
Journal:  Eur Respir J       Date:  2014-03       Impact factor: 16.671

Review 5.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary.

Authors:  R A Pauwels; A S Buist; P M Calverley; C R Jenkins; S S Hurd
Journal:  Am J Respir Crit Care Med       Date:  2001-04       Impact factor: 21.405

Review 6.  Clinical phenotypes of COPD: identification, definition and implications for guidelines.

Authors:  Marc Miravitlles; Myriam Calle; Juan José Soler-Cataluña
Journal:  Arch Bronconeumol       Date:  2011-12-22       Impact factor: 4.872

7.  Targeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease.

Authors:  Yasuo To; Kazuhiro Ito; Yasuo Kizawa; Marco Failla; Misako Ito; Tadashi Kusama; W Mark Elliott; James C Hogg; Ian M Adcock; Peter J Barnes
Journal:  Am J Respir Crit Care Med       Date:  2010-03-11       Impact factor: 21.405

8.  Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials.

Authors:  Peter M A Calverley; Klaus F Rabe; Udo-Michael Goehring; Søren Kristiansen; Leonardo M Fabbri; Fernando J Martinez
Journal:  Lancet       Date:  2009-08-29       Impact factor: 79.321

Review 9.  Immunology of asthma and chronic obstructive pulmonary disease.

Authors:  Peter J Barnes
Journal:  Nat Rev Immunol       Date:  2008-02-15       Impact factor: 53.106

Review 10.  New anti-inflammatory targets for chronic obstructive pulmonary disease.

Authors:  Peter J Barnes
Journal:  Nat Rev Drug Discov       Date:  2013-07       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.